AMRX vs TROW · P/E 44, rev $2.79B vs P/E 12, rev $7.09B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported TROW revenue for 2024-12-31 was $7.09B. Net income was $2.14B. Revenue was up 9.8% from 2023-12-31 to 2024-12-31. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the AMRX and TROW stock pages for the full models.
Not investment advice.